trial

A Study of HS-10380 in Chinese Participants

NCTId NCT05480592
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Unknown
Enrollment 76 (estimated)
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Primary completion 2023-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Unknown
Enrollment
76 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Quadruple
Start
2022-08-01
Primary completion
2023-06-30
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
HS-10380

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead Sponsor

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
76
Phase
PHASE1
Primary Completion Date
2023-06-30
Status
UNKNOWN
relationships
The graph out of here
drug
HS-10380
drug
lead_sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication